On May 31, 2019, Mabpharm Limited (“Mabpharm” or “Company”, 2181.HK) successfully listed on the Hong Kong Stock Exchange (“HKEx”). The pre-green shoe offering size is US$ 150 million and the post-green shoe offering size is US$ 172 million (the “Offering”). CICC acted as Sole Sponsor, Sole Global Coordinator, Sole Bookrunner and Sole Lead Manager for the Offering. This Offering represents a new milestone to the new Chapter 18A since adopted by HKEx in 2018 after CICC has successfully assisted the biopharmaceutical companies such as BeiGene, Junshi Biosciences and CanSino Biologics to list on the Main Board of HKEx. 

Mabpharm is a leading biopharmaceutical company in China, focusing on the research, development and production of new drugs and biosimilar for cancers and autoimmune diseases. Mabpharm strives to bring to market high quality and affordable innovative biologics through its efficient R&D system and low-cost pharmaceutical production capability, and develop differentiated therapeutic products by fully utilizing Company’s extensive R&D experience. Mabpharm ‘s pipeline of drug candidates currently consists of nine monoclonal antibody drugs, three of which are Core Products under phase III clinical trials: CMAB007 (omalizumab), CMAB009 (cetuximab) and CMAB008 (infliximab). In addition, two other drug candidates, CMAB809 (trastuzumab) and CMAB819 (nivolumab), have obtained approval for clinical trials. Mabpharm has strong capabilities of internal research, preclinical research, clinical research and production capacity, and is building its sales and marketing team to prepare for the commercialization of Company’s product candidates. Core R&D team members of Mabpharm have more than 16 years of biopharmaceutical experience, and have led several national-level scientific research projects including three major projects under the “863” Program. Mabpharm 's production site in Taizhou, currently equipped with a 3*1,500L bioreactor system, is one of the largest antibody drug production facilities in China in terms of production capacity.

As the Sole Sponsor, Sole Global Coordinator, Sole Bookrunner and Sole Lead Manager of the Offering, CICC independently assisted the Company to successfully introduced investors to meet all demands, including the cornerstone investor – 3SBio (1530.HK), long-term international funds, well-known hedge funds and professional healthcare investors, and ensured that this Offering was highly recognized by the Company.

As a leading Investment Bank with “China Roots, International Reach”, CICC will continue to utilize its capital market expertise as well as its seamless cooperation of onshore and offshore business network to provide continuous support to our customers in terms of introducing global investor’s base, reaching out to international capital market, and promoting global business development.